# Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

> **NCT02461927** · PHASE1,PHASE2 · COMPLETED · sponsor: **VA Office of Research and Development** · enrollment: 65 (actual)

## Conditions studied

- Major Depressive Disorder
- Alcohol Use Disorder

## Interventions

- **DRUG:** Ketamine + Naltrexone
- **DRUG:** Ketamine + Placebo
- **DRUG:** Placebo (psychoactive placebo midazolam) + Placebo

## Key facts

- **NCT ID:** NCT02461927
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-01
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-10-30
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02461927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02461927, "Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02461927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*